Updated: Novartis Ceo Vas Narasimhan Restructures The Pharma Giant, Cutting Fees $1b+, Ousting Best Execs And Signaling Layoffs Ahead Endpoints News
So when I speak about moving to the 1st line, Scemblix, which would be on Slide 14. We continue to see robust launch momentum where we have Q3 sales driven in aspect by — Q3 sales had been $41 million, and we had a...
